Keshu Zhou
13PUBLICATIONS
77CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (13)
Sort by Publication Date:
|Feb 24, 2026
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.Yan Xie, Ke-Shu Zhou, Lan-Fang Li
|Aug 14, 2025
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.Yan Xie, Ke-Shu Zhou, Lan-Fang Li
|Sep 24, 2024
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna
|Sep 19, 2024
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma.Jie Jin, Hong Cen, Keshu Zhou
|Jun 07, 2024
Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment via Deep Learning and Molecular Docking.Hao Guo, Zhe-Yuan Shen, Yong-Yi Yuan
|Sep 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.Yuqin Song, Keshu Zhou, Dehui Zou
Pageof 3
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=75)
